Molecular Partners (NASDAQ:MOLN) Posts Earnings Results, Misses Estimates By $0.03 EPS

Molecular Partners (NASDAQ:MOLN) issued its quarterly earnings data on Tuesday. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.03), Zacks reports.

Molecular Partners Stock Down 5.1%

Shares of Molecular Partners stock traded down $0.21 on Thursday, reaching $3.80. 611 shares of the stock were exchanged, compared to its average volume of 4,209. The business has a 50 day moving average price of $4.36 and a two-hundred day moving average price of $4.33. The firm has a market capitalization of $153.24 million, a price-to-earnings ratio of -1.96 and a beta of 1.08. Molecular Partners has a twelve month low of $3.41 and a twelve month high of $5.36.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on MOLN. TD Cowen restated a “buy” rating on shares of Molecular Partners in a report on Monday, March 16th. HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Molecular Partners in a research note on Wednesday, April 22nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Molecular Partners in a research report on Friday, April 10th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Molecular Partners currently has an average rating of “Hold” and a consensus price target of $8.38.

Institutional Trading of Molecular Partners

A hedge fund recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC purchased a new stake in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,311 shares of the company’s stock, valued at approximately $54,000. Institutional investors own 26.55% of the company’s stock.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.